Drug intelligence / Profile preview

Phecda Medicine mitophagy inducer

Development stage: Preclinical
Lead developer: Phecda Medicine
Modality: Small Molecules
Administration: Intravenous, Intra-arterial, Intraperitoneal, Subcutaneous, Transdermal, Intratracheal, Intramuscular, Topical, Intradermal, Intranasal, Pulmonary, Inhalation, Intrabronchial, Oral, Rectal

Overview

Phecda Medicine's mitophagy inducer is a preclinical small-molecule therapeutic designed to selectively trigger mitochondrial autophagy (mitophagy). The drug specifically targets damaged mitochondria for degradation, thereby maintaining cellular homeostasis and preventing the accumulation of dysfunctional organelles that contribute to disease progression. Developed by Phecda Medicine (Hangzhou Phecda Medicine Biotechnology), this compound is being explored for its potential in treating a broad spectrum of conditions, including neurological, cardiovascular, liver, and kidney diseases, as well as diabetes and cancers associated with the DNA damage response (DDR). By restoring mitochondrial quality control, the therapy aims to address the underlying pathophysiology of these diverse degenerative and metabolic disorders.

Other names: Phecda Medicine-damaged mitochondria-mitophagy pathway-small molecule-neurological diseases-cardiovascular diseases-liver diseases-kidney diseases-diabetes-DNA damage response-related cancers

Beyond the preview

Go deeper on Phecda Medicine mitophagy inducer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phecda Medicine mitophagy inducer.

Explore the full profile